Currents in Contemporary Ethics

Eichenwald K. Kolata G. , “Drug Trials Hide Conflict for Doctors,” New York Times, May 16, 1999, at A1.

Cech T. Leonard J. , “Conflicts of Interests—Moving Beyond Disclosure,” Science, 291 (2001): 989;

Pearlman Heidi , “Top Medical Schools Seek End to Conflict of Interest Concerns,” Associated Press, February 8, 2001.

Office for Human Research Protections, Financial Relationships in Clinical Trials: Issues for Institutions, Clinical Investigators, and IRBs to Consider When Dealing with Issues of Financial Interests and Human Subject Protection, Draft Interim Guidance (January 10, 2001), available at <http://ohrp.osophs.dhhs.gov/humansubjects/finreltn/finmain.htm>.

Hailey D. , “Scientific Harassment by Pharmaceutical Companies: Time to Stop,” Canadian Medical Association Journal, 162 (2000): 212–13;.

Horton R. , “Conflicts of Interest in Clinical Research: Opprobrium or Obsession?,” Lancet, 349 (1997): 1112.

Boyd E. , “Assessing Faculty Financial Relationships with Industry: A Case Study,” JAMA, 284 (2000): 2209–14.

Goldner J. , “Dealing with Conflicts of Interest in Biomedical Research: IRB Oversight as the Next Best Solution to the Abolitionist Approach,” Journal of Law, Medicine & Ethics, 28 (2000): 379–404.

U.S. General Accounting Office, Report to Congressional Requesters, NIH Clinical Trials: Various Factors Affect Patient Participation, GAO/HEHS-99-182 (Washington, D.C.: General Accounting Office, 1999), available at <http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.21&filename=he99182.pdf&directory=/diskb/wais/data/gao>.

Bodenheimer T. , “Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry,” N. Engl. J. Med., 342 (2000): 1539–44.

DeRenzo E. , “Coercion in the Recruitment and Retention of Human Research Subjects, Pharmaceutical Industry Payments to Physician-Investigators and the Moral Courage of the IRB,” IRB, 22 (2000): 1–5.

Bodenheimer , supra note 8.

Office of the Inspector General, Department of Health and Human Services, Recruiting Human Subjects: Pressures in Industry-Sponsored Clinical Research, OE1-01-97-00195 (Washington, D.C.: Department of Health and Human Services, June 2000), available at <http://oig.hhs.gov/oei/summaries/b459.pdf>.

DeRenzo , supra note 9.

DeAngelis C. , “Conflict of Interest and the Public Trust,” JAMA, 285 (2000): 2237–38.

Office for Human Research Protections, supra note 3.

General Medical Council, Medical Research: The Role and Responsibilities of Doctors, Draft Guidance (March 2001), searchable at <http://www.gmc-uk.org/global_sections/search_frameset.htm>.

Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (August 1998), available at <http://www.nserc.ca/programs/ethics/english/ethics-e.pdf>.

See also Australian National Health and Medical Research Council, National Statement on Ethical Conduct in Research Involving Humans (June 1999), available at <http://www.health.gov.au/nhmrc/publications/humans/preamble.htm>.

Office for Human Research Protections, supra note 3.

Medical Research Council of Canada, supra note 16.

Canadian Medical Association, “Physicians and the Pharmaceutical Industry,” Canadian Medical Association Journal, 164 (2001): 1339–41.

DeRenzo , supra note 9.

Cech Leonard , supra note 2.

Caulfield T. , “Globalization, Conflicts of Interest and Clinical Research: An Overview of Trends and Issues,” Widener Law Symposium Journal, 8 (2001): 31–45.

McDonald M. , The Governance of Health Research Involving Human Subjects (May 2000). Report commissioned by the Law Commission of Canada, available at <http://www.lcc.gc.ca/en/themes/gr/hrish/macdonald/macdonald.pdf>.

Friedberg M. , “Evaluation of Conflict of Interest in Economic Analysis of New Drug Trials in Oncology,” JAMA, 282 (1999): 1453–57.

DeRenzo , supra note 9;.

Goldner , supra note 6.

U.S. General Accounting Office, supra note 7.